This bill requires the Government Accountability Office to study how prescription drug prices affect payments and compensation throughout the drug supply chain, including payments between pharmaceutical manufacturers, wholesalers, pharmacy benefit managers, pharmacies, and insurance plans. The study must examine the types and amounts of price-related fees, how different companies structure their compensation, potential conflicts of interest where higher drug prices could benefit middlemen financially, and trends in these payment structures over time. The legislation is particularly focused on understanding whether the current system incentivizes companies to favor more expensive drugs over cheaper alternatives. The GAO must complete this comprehensive study and submit findings and recommendations to Congress within two years of the bill's enactment, with no specific funding amount designated in the legislation. This bill affects drug manufacturers, insurance companies, pharmacies, and ultimately consumers who pay for prescription medications.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.